Emmanuelle Waubant

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/90000/publications.pdf

Version: 2024-02-01

157 papers	25,356 citations	41323 49 h-index	8156 148 g-index
160 all docs	160 docs citations	160 times ranked	19546 citing authors

#	Article	IF	Citations
1	Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria. Annals of Neurology, 2011, 69, 292-302.	2.8	8,001
2	Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurology, The, 2018, 17, 162-173.	4.9	4,605
3	Defining the clinical course of multiple sclerosis. Neurology, 2014, 83, 278-286.	1.5	2,344
4	B-Cell Depletion with Rituximab in Relapsingâ€“Remitting Multiple Sclerosis. New England Journal of Medicine, 2008, 358, 676-688.	13.9	2,107
5	Rituximab in relapsingâ€remitting multiple sclerosis: A 72â€week, openâ€label, phase I trial. Annals of Neurology, 2008, 63, 395-400.	2.8	484
6	The gut microbiome in human neurological disease: A review. Annals of Neurology, 2017, 81, 369-382.	2.8	388
7	Gut Microbiota in Multiple Sclerosis: Possible Influence of Immunomodulators. Journal of Investigative Medicine, 2015, 63, 729-734.	0.7	309
8	Vitamin D status is associated with relapse rate in pediatricâ€onset multiple sclerosis. Annals of Neurology, 2010, 67, 618-624.	2.8	294
9	Clinical features and viral serologies in children with multiple sclerosis: a multinational observational study. Lancet Neurology, The, 2007, 6, 773-781.	4.9	292
10	Interferon beta-1b inhibits gelatinase secretion and in vitro migration of human T cells: A possible mechanism for treatment efficacy in multiple sclerosis. Annals of Neurology, 1996, 40, 846-852.	2.8	279
11	Myelin-oligodendrocyte glycoprotein antibody-associated disease. Lancet Neurology, The, 2021, 20, 762-772.	4.9	261
12	Gut microbiota in early pediatric multiple sclerosis: a caseâˆ’control study. European Journal of Neurology, 2016, 23, 1308-1321.	1.7	260
13	Trial of Fingolimod versus Interferon Beta-1a in Pediatric Multiple Sclerosis. New England Journal of Medicine, 2018, 379, 1017-1027.	13.9	237
14	Vitamin D status predicts new brain magnetic resonance imaging activity in multiple sclerosis. Annals of Neurology, 2012, 72, 234-240.	2.8	220
15	Rebound Syndrome in Patients With Multiple Sclerosis After Cessation of Fingolimod Treatment. JAMA Neurology, 2016, 73, 790.	4.5	177
16	Serum neurofilament is associated with progression of brain atrophy and disability in early MS. Neurology, 2017, 88, 826-831.	1.5	168
17	Environmental and genetic risk factors for MS: an integrated review. Annals of Clinical and Translational Neurology, 2019, 6, 1905-1922.	1.7	165
18	Difference in Disease Burden and Activity in Pediatric Patients on Brain Magnetic Resonance Imaging at Time of Multiple Sclerosis Onset vs Adults. Archives of Neurology, 2009, 66, 967-71.	4.9	159

#	Article	IF	Citations
19	Spinal cord gray matter atrophy correlates with multiple sclerosis disability. Annals of Neurology, 2014, 76, 568-580.	2.8	158
20	The COVID-19 pandemic and the use of MS disease-modifying therapies. Multiple Sclerosis and Related Disorders, 2020, 39, 102073.	0.9	153
21	Evidence for a causal relationship between low vitamin D, high BMI, and pediatric-onset MS. Neurology, 2017, 88, 1623-1629.	1.5	138
22	Gut microbiota composition and relapse risk in pediatric MS: A pilot study. Journal of the Neurological Sciences, 2016, 363, 153-157.	0.3	137
23	Pediatric multiple sclerosis. Nature Reviews Neurology, 2009, 5, 621-631.	4.9	124
24	Acute Flaccid Myelitis of Unknown Etiology in California, 2012-2015. JAMA - Journal of the American Medical Association, 2015, 314, 2663.	3.8	118
25	Spinal cord involvement in multiple sclerosis and neuromyelitis optica spectrum disorders. Lancet Neurology, The, 2019, 18, 185-197.	4.9	110
26	Bile acid metabolism is altered in multiple sclerosis and supplementation ameliorates neuroinflammation. Journal of Clinical Investigation, 2020, 130, 3467-3482.	3.9	109
27	The multiple sclerosis gut microbiota: A systematic review. Multiple Sclerosis and Related Disorders, 2020, 37, 101427.	0.9	102
28	Multiple Sclerosis Therapies in Pediatric Patients With Refractory Multiple Sclerosis. Archives of Neurology, 2011, 68, 437.	4.9	101
29	Environmental modifiable risk factors for multiple sclerosis: Report from the 2016 ECTRIMS focused workshop. Multiple Sclerosis Journal, 2018, 24, 590-603.	1.4	101
30	Clinical features of neuromyelitis optica in children. Neurology, 2016, 86, 245-252.	1.5	100
31	Safety and efficacy of amantadine, modafinil, and methylphenidate for fatigue in multiple sclerosis: a randomised, placebo-controlled, crossover, double-blind trial. Lancet Neurology, The, 2021, 20, 38-48.	4.9	90
32	Characteristics of Children and Adolescents With Multiple Sclerosis. Pediatrics, 2016, 138, .	1.0	89
33	Association Between Thoracic Spinal Cord Gray Matter Atrophy and Disability in Multiple Sclerosis. JAMA Neurology, 2015, 72, 897.	4.5	78
34	Contribution of dietary intake to relapse rate in early paediatric multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 28-33.	0.9	74
35	Realâ€World Effectiveness of Initial Diseaseâ€Modifying Therapies in Pediatric <scp>Multiple Sclerosis</scp>. Annals of Neurology, 2020, 88, 42-55.	2.8	68
36	Distinct effects of obesity and puberty on risk and age at onset of pediatric MS. Annals of Clinical and Translational Neurology, 2016, 3, 897-907.	1.7	67

#	Article	IF	Citations
37	Clinical predictors of early second event in patients with clinically isolated syndrome. Journal of Neurology, 2009, 256, 1061-1066.	1.8	66
38	Body mass index, but not vitamin D status, is associated with brain volume change in MS. Neurology, 2018, 91, e2256-e2264.	1.5	65
39	The Vitamin D to Ameliorate Multiple Sclerosis (VIDAMS) trial: Study design for a multicenter, randomized, double-blind controlled trial of vitamin D in multiple sclerosis. Contemporary Clinical Trials, 2014, 39, 288-293.	0.8	64
40	Patient centered decision making: Use of conjoint analysis to determine riskâ€“benefit trade-offs for preference sensitive treatment choices. Journal of the Neurological Sciences, 2014, 344, 80-87.	0.3	64
41	Patient Preferences for Attributes of Multiple Sclerosis Disease-Modifying Therapies. International Journal of MS Care, 2015, 17, 74-82.	0.4	64
42	Recommendations for observational studies of comorbidity in multiple sclerosis. Neurology, 2016, 86, 1446-1453.	1.5	64
43	Clinical trials of disease-modifying agents in pediatric MS. Neurology, 2019, 92, e2538-e2549.	1.5	62
44	Association Between Breastfeeding and Postpartum Multiple Sclerosis Relapses. JAMA Neurology, 2020, 77, 327.	4.5	60
45	Dietary salt intake and time to relapse in paediatric multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, 1350-1353.	0.9	58
46	A case-control study of dietary salt intake in pediatric-onset multiple sclerosis. Multiple Sclerosis and Related Disorders, 2016, 6, 87-92.	0.9	58
47	Rituximab Use in Pediatric Central Demyelinating Disease. Pediatric Neurology, 2014, 51, 114-118.	1.0	57
48	Relapse severity and recovery in early pediatric multiple sclerosis. Multiple Sclerosis Journal, 2012, 18, 1008-1012.	1.4	55
49	Altered tryptophan metabolism is associated with pediatric multiple sclerosis risk and course. Annals of Clinical and Translational Neurology, 2018, 5, 1211-1221.	1.7	55
50	Use of newer disease-modifying therapies in pediatric multiple sclerosis in the US. Neurology, 2018, 91, e1778-e1787.	1.5	55
51	Pediatric Multiple Sclerosis. Neurologic Clinics, 2011, 29, 481-505.	0.8	53
52	Switching Multiple Sclerosis Patients with Breakthrough Disease to Second-Line Therapy. PLoS ONE, 2011, 6, e16664.	1.1	51
53	Menarche increases relapse risk in pediatric multiple sclerosis. Multiple Sclerosis Journal, 2016, 22, 193-200.	1.4	50
54	Multiple sclerosis patients have a diminished serologic response to vitamin D supplementation compared to healthy controls. Multiple Sclerosis Journal, 2016, 22, 753-760.	1.4	49

#	Article	IF	Citations
55	The challenge of comorbidity in clinical trials for multiple sclerosis. Neurology, 2016, 86, 1437-1445.	1.5	48
56	Admixture mapping reveals evidence of differential multiple sclerosis risk by genetic ancestry. PLoS Genetics, 2019, 15, e1007808.	1.5	48
57	Improved relapse recovery in paediatric compared to adult multiple sclerosis. Brain, 2020, 143, 2733-2741.	3.7	45
58	Ovarian aging is associated with gray matter volume and disability in women with MS. Neurology, 2018, 90, e254-e260.	1.5	41
59	Multiple Sclerosis Susceptibility Genes: Associations with Relapse Severity and Recovery. PLoS ONE, 2013, 8, e75416.	1.1	40
60	Maternal and Perinatal Exposures Are Associated With Risk for Pediatric-Onset Multiple Sclerosis. Pediatrics, 2017, 139, e20162838.	1.0	40
61	Spinal Cord Atrophy Predicts Progressive Disease in Relapsing Multiple Sclerosis. Annals of Neurology, 2022, 91, 268-281.	2.8	39
62	Environmental and genetic factors in pediatric inflammatory demyelinating diseases. Neurology, 2016, 87, S20-7.	1.5	37
63	Genetic risk factors for pediatric-onset multiple sclerosis. Multiple Sclerosis Journal, 2018, 24, 1825-1834.	1.4	37
64	Longitudinal associations between brain structural changes and fatigue in early MS. Multiple Sclerosis and Related Disorders, 2016, 5, 29-33.	0.9	36
65	The gut microbiota in pediatric multiple sclerosis and demyelinating syndromes. Annals of Clinical and Translational Neurology, 2021, 8, 2252-2269.	1.7	34
66	A randomized controlled phase II trial of riluzole in early multiple sclerosis. Annals of Clinical and Translational Neurology, 2014, 1, 340-347.	1.7	33
67	Antibody response to common viruses and human leukocyte antigen-DRB1 in pediatric multiple sclerosis. Multiple Sclerosis Journal, 2013, 19, 891-895.	1.4	32
68	Effects of rituximab on lymphocytes in multiple sclerosis and neuromyelitis optica. Multiple Sclerosis and Related Disorders, 2014, 3, 244-252.	0.9	32
69	Urban air quality and associations with pediatric multiple sclerosis. Annals of Clinical and Translational Neurology, 2018, 5, 1146-1153.	1.7	29
70	Pediatric multiple sclerosis. Current Treatment Options in Neurology, 2009, 11, 203-210.	0.7	28
71	Longitudinal associations between MRI and cognitive changes in very early MS. Multiple Sclerosis and Related Disorders, 2016, 5, 47-52.	0.9	28
72	Dietary factors and pediatric multiple sclerosis: A case-control study. Multiple Sclerosis Journal, 2018, 24, 1067-1076.	1.4	27

#	Article	IF	Citations
73	Pediatric multiple sclerosis. Current Neurology and Neuroscience Reports, 2008, 8, 434-441.	2.0	26
74	Magnetic resonance imaging correlates of clinical outcomes in early multiple sclerosis. Multiple Sclerosis and Related Disorders, 2014, 3, 720-727.	0.9	26
75	Effect of fingolimod on MRI outcomes in patients with paediatric-onset multiple sclerosis: results from the phase 3 PARADIGMS study. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 483-492.	0.9	26
76	Multi-omic evaluation of metabolic alterations in multiple sclerosis identifies shifts in aromatic amino acid metabolism. Cell Reports Medicine, 2021, 2, 100424.	3.3	26
77	Heterogeneity in association of remote herpesvirus infections and pediatric <scp>MS</scp>. Annals of Clinical and Translational Neurology, 2018, 5, 1222-1228.	1.7	25
78	A validation study for remote testing of cognitive function in multiple sclerosis. Multiple Sclerosis Journal, 2021, 27, 795-798.	1.4	25
79	Treatment of multiple sclerosis in children and adolescents. Expert Opinion on Pharmacotherapy, 2010, 11, 505-520.	0.9	24
80	Protective environmental factors for neuromyelitis optica. Neurology, 2014, 83, 1923-1929.	1.5	23
81	Genetic predictors of relapse rate in pediatric MS. Multiple Sclerosis Journal, 2016, 22, 1528-1535.	1.4	23
82	Consistent control of disease activity with fingolimod versus IFN Î²-1a in paediatric-onset multiple sclerosis: further insights from PARADIGMS. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 91, jnnp-2019-321124.	0.9	22
83	The US Network of Pediatric Multiple Sclerosis Centers. Journal of Child Neurology, 2015, 30, 1381-1387.	0.7	21
84	Neuropsychological correlates of multiple sclerosis across the lifespan. Multiple Sclerosis Journal, 2015, 21, 1355-1364.	1.4	21
85	Examining the contributions of environmental quality to pediatric multiple sclerosis. Multiple Sclerosis and Related Disorders, 2017, 18, 164-169.	0.9	21
86	Genetic variation in the geneLRP2increases relapse risk in multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, 864-868.	0.9	21
87	Gut microbiome is associated with multiple sclerosis activity in children. Annals of Clinical and Translational Neurology, 2021, 8, 1867-1883.	1.7	21
88	EDSS variability before randomization may limit treatment discovery in primary progressive MS. Multiple Sclerosis Journal, 2013, 19, 775-781.	1.4	19
89	International Pediatric MS Study Group Global Members Symposium report. Neurology, 2016, 87, S110-6.	1.5	19
90	Sex differences and subclinical retinal injury in pediatric-onset MS. Multiple Sclerosis Journal, 2017, 23, 447-455.	1.4	19

#	Article	IF	Citations
91	Rituximab in patients with pediatric multiple sclerosis and other demyelinating disorders of the CNS: Practical considerations. Multiple Sclerosis Journal, 2021, 27, 1814-1822.	1.4	19
92	Neuroprotection in Multiple Sclerosis: A Therapeutic Approach. CNS Drugs, 2013, 27, 799-815.	2.7	18
93	A retrospective cohort study of plasma exchange in central nervous system demyelinating events in children. Multiple Sclerosis and Related Disorders, 2019, 35, 50-54.	0.9	18
94	Implementing the 2017 McDonald criteria for the diagnosis of multiple sclerosis. Nature Reviews Neurology, 2019, 15, 441-445.	4.9	18
95	Seafood, fatty acid biosynthesis genes, and multiple sclerosis susceptibility. Multiple Sclerosis Journal, 2020, 26, 1476-1485.	1.4	18
96	Cognitive processing speed in pediatric-onset multiple sclerosis: Baseline characteristics of impairment and prediction of decline. Multiple Sclerosis Journal, 2020, 26, 1938-1947.	1.4	18
97	Vitamin D genes influence MS relapses in children. Multiple Sclerosis Journal, 2020, 26, 894-901.	1.4	17
98	Prolonged Remission in Neuromyelitis Optica Following Cessation of Rituximab Treatment. Journal of Child Neurology, 2015, 30, 1366-1370.	0.7	16
99	Treatment of fatigue with methylphenidate, modafinil and amantadine in multiple sclerosis (TRIUMPHANT-MS): Study design for a pragmatic, randomized, double-blind, crossover clinical trial. Contemporary Clinical Trials, 2018, 64, 67-76.	0.8	16
100	<scp>Multiple Sclerosis</scp> Is Rare in Epsteinâ€“Barr Virusâ€“Seronegative Children with <scp>Central Nervous System</scp> Inflammatory Demyelination. Annals of Neurology, 2021, 89, 1234-1239.	2.8	16
101	High titers of myelin oligodendrocyte glycoprotein antibody are only observed close to clinical events in pediatrics. Multiple Sclerosis and Related Disorders, 2021, 56, 103253.	0.9	16
102	The multiple sclerosis risk allele within the AHI1 gene is associated with relapses in children and adults. Multiple Sclerosis and Related Disorders, 2018, 19, 161-165.	0.9	15
103	Metagenomic Analysis of the Pediatric-Onset Multiple Sclerosis Gut Microbiome. Neurology, 2022, 98, .	1.5	15
104	Neurite Orientation Dispersion and Density Imaging for Assessing Acute Inflammation and Lesion Evolution in MS. American Journal of Neuroradiology, 2020, 41, 2219-2226.	1.2	14
105	Association of Multiple Sclerosis Susceptibility Variants and Early Attack Location in the CNS. PLoS ONE, 2013, 8, e75565.	1.1	14
106	Subcortical grey matter volumes predict subsequent walking function in early multiple sclerosis. Journal of the Neurological Sciences, 2016, 366, 229-233.	0.3	13
107	The â€˜Field Hypothesisâ€™: rebound activity after stopping disease-modifying therapies. Multiple Sclerosis and Related Disorders, 2017, 15, A1-A2.	0.9	13
108	Association Between Glutamate Blockade and Fatigue in Patients With Multiple Sclerosis. JAMA Neurology, 2015, 72, 1374.	4.5	12

#	Article	IF	Citations
109	Pediatric glial fibrillary acidic protein meningoencephalomyelitis: A case report and review of the literature. Multiple Sclerosis and Related Disorders, 2019, 29, 148-152.	0.9	12
110	Prevalence of salivary human herpesviruses in pediatric multiple sclerosis cases and controls. Multiple Sclerosis Journal, 2019, 25, 644-652.	1.4	12
111	Ocrelizumab exposure in the second trimester of pregnancy without neonatal B-cell depletion. Multiple Sclerosis and Related Disorders, 2020, 45, 102398.	0.9	12
112	Autoimmune Encephalitis in Children: A Case Series at a Tertiary Care Center. Journal of Child Neurology, 2020, 35, 591-599.	0.7	12
113	Association Between Time Spent Outdoors and Risk of Multiple Sclerosis. Neurology, 2022, 98, .	1.5	12
114	Pediatric Multiple Sclerosis Severity Score in a large US cohort. Neurology, 2020, 95, e1844-e1853.	1.5	11
115	Longitudinally Extensive Optic Neuritis in Pediatric Patients. Journal of Child Neurology, 2015, 30, 120-123.	0.7	10
116	mi RNA contributions to pediatricâ€onset multiple sclerosis inferred from GWAS. Annals of Clinical and Translational Neurology, 2019, 6, 1053-1061.	1.7	10
117	Biopsy-Supported Tumefactive Demyelination of the Central Nervous System in Children. Journal of Child Neurology, 2016, 31, 1528-1533.	0.7	9
118	A pilot study of oxidative pathways in MS fatigue: randomized trial of Nâ€acetyl cysteine. Annals of Clinical and Translational Neurology, 2021, 8, 811-824.	1.7	8
119	Geneâ€“environment interactions increase the risk of pediatric-onset multiple sclerosis associated with ozone pollution. Multiple Sclerosis Journal, 2022, 28, 1330-1339.	1.4	8
120	The metabolic potential of the paediatric-onset multiple sclerosis gut microbiome. Multiple Sclerosis and Related Disorders, 2022, 63, 103829.	0.9	8
121	MS and related disorders: groundbreaking news. Lancet Neurology, The, 2014, 13, 11-13.	4.9	7
122	Puberty onset and pediatric multiple sclerosis activity in boys. Multiple Sclerosis and Related Disorders, 2019, 27, 184-187.	0.9	7
123	Subclinical Saccadic Eye Movement Dysfunction in Pediatric Multiple Sclerosis. Journal of Child Neurology, 2019, 34, 38-43.	0.7	7
124	Ethical considerations in the treatment of multiple sclerosis fatigue. Multiple Sclerosis and Related Disorders, 2021, 54, 103129.	0.9	7
125	Biosensor vital sign detects multiple sclerosis progression. Annals of Clinical and Translational Neurology, 2021, 8, 4-14.	1.7	6
126	B-cell depletion in children with neuroimmunologic conditions. Neurology, 2014, 83, 111-112.	1.5	5

#	Article	IF	Citations
127	Performance of 2010 McDonald criteria and 2016 MAGNIMS guidelines in the diagnosis of primary progressive multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 550-552.	0.9	5
128	Introducing the International Women in Multiple Sclerosis network. Lancet Neurology, The, 2019, 18, 521.	4.9	5
129	Clinical Features and Outcomes of Pediatric Monophasic and Recurrent Idiopathic Optic Neuritis. Journal of Child Neurology, 2020, 35, 77-83.	0.7	5
130	Temporal profile of lymphocyte counts and relationship with infections with fingolimod therapy in paediatric patients with multiple sclerosis: Results from the PARADIGMS study. Multiple Sclerosis Journal, 2021, 27, 922-932.	1.4	5
131	Therapeutic Advances in Pediatric Multiple Sclerosis. Journal of Pediatrics, 2013, 163, 631-637.	0.9	4
132	Rebound Syndrome in Multiple Sclerosis After Fingolimod Cessationâ€"Reply. JAMA Neurology, 2016, 73, 1376.	4.5	4
133	Safety evaluation of shorter infusion for ocrelizumab in a substudy of the Phase IIIb CHORDS trial. Annals of Clinical and Translational Neurology, 2021, 8, 711-715.	1.7	4
134	Familial History of Autoimmune Disorders Among Patients With Pediatric Multiple Sclerosis. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, .	3.1	4
135	Treatment Options in Multiple Sclerosis. Journal of Clinical Psychiatry, 2012, 73, e22.	1.1	4
136	Preventing Multiple Sclerosis: The Pediatric Perspective. Frontiers in Neurology, 2022, 13, 802380.	1.1	4
137	Effect of fingolimod on health-related quality of life in paediatric patients with multiple sclerosis: results from the phase 3 PARADIGMS Study. BMJ Neurology Open, 2022, 4, e000215.	0.7	4
138	Paediatric multiple sclerosis: a lesson from TERIKIDS. Lancet Neurology, The, 2021, 20, 971-973.	4.9	4
139	Konsensusprotokoll zur Standardisierung von Entnahme und Biobanking des Liquor cerebrospinalis / A consensus protocol for the standardisation of cerebrospinal fluid collection and biobanking. Laboratoriums Medizin, 2010, 34, 1-12.	0.1	3
140	PEDIATRIC MULTIPLE SCLEROSIS. CONTINUUM Lifelong Learning in Neurology, 2010, 16, 181-192.	0.4	2
141	Neurodegeneration and Remyelination in Multiple Sclerosis. , 2016, , 311-337.		2
142	Do you believe in Gad?. Multiple Sclerosis and Related Disorders, 2020, 44, 102299.	0.9	2
143	Increased Prevalence of Familial Autoimmune Disease in Children With Opsoclonus-Myoclonus Syndrome. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, e1079.	3.1	2
144	Stability of the gut microbiota in persons with paediatric-onset multiple sclerosis and related demyelinating diseases. Multiple Sclerosis Journal, 2022, 28, 1819-1824.	1.4	2

#	Article	IF	Citations
145	Clinical Reasoning: A 16-year-old girl with subacute weakness and sensory loss. Neurology, 2017, 88, e225-e229.	1.5	1
146	Mind the gap. Neurology, 2019, 92, 698-699.	1.5	1
147	New onset myoclonus and encephalopathy in a woman with multiple sclerosis: Consider the medications. Neuroimmunology Reports, 2021, 1, 100020.	0.2	1
148	Etiological research in pediatric multiple sclerosis: A tool to assess environmental exposures (PEDiatric Italian Genetic and enviRonment ExposurE Questionnaire). Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2021, 7, 205521732110590.	0.5	1
149	Acute transverse myelitis and silent infection with Mycoplasma pneumoniae. Journal of Pediatric Neurology, 2015, 12, 145-149.	0.0	0
150	Clinical Reasoning: Left hemiparesis, ataxia, and optic neuritis in a child previously treated for pineoblastoma. Neurology, 2016, 86, e161-e165.	1.5	0
151	Clinical trials for pediatric MS should be prioritized to test only one or two of the most promising agents â€“ NO. Multiple Sclerosis Journal, 2016, 22, 1651-1653.	1.4	0
152	Executive Functioning in Pediatric Multiple Sclerosis: Considering the Impact of Emotional and Psychosocial Factors. Journal of Pediatric Neuropsychology, 2017, 3, 206-217.	0.3	0
153	Two-armed active comparator trials are unethical in paediatric multiple sclerosis â€“ Commentary. Multiple Sclerosis Journal, 2020, 26, 1474-1475.	1.4	0
154	The future of microbiome research in neuroinflammatory disorders. Multiple Sclerosis and Related Disorders, 2020, 40, 102098.	0.9	0
155	Incidence of Acute Disseminated Encephalomyelitis in China: First National Survey. Neuroscience Bulletin, 2021, 37, 761-762.	1.5	0
156	Early Recognition and Diagnosis of Multiple Sclerosis. Journal of Clinical Psychiatry, 2012, 73, e14.	1.1	0
157	Reply to â€œSpinal Cord Atrophy Is a Preclinical Marker of Progressive <scp>MS</scp>â€• Annals of Neurology, 2022, 91, 735-736.	2.8	0